Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene
BACKGROUND: Nemaline myopathy (NM), the most common non-dystrophic congenital myopathy, is characterized by generalized skeletal muscle weakness, often from birth. To date, no therapy exists that enhances the contractile strength of muscles of NM patients. Mutations in NEB, encoding the giant protei...
Main Authors: | , , , , , , , , |
---|---|
Other Authors: | |
Language: | en |
Published: |
BioMed Central
2015
|
Subjects: | |
Online Access: | http://hdl.handle.net/10150/610333 http://arizona.openrepository.com/arizona/handle/10150/610333 |
id |
ndltd-arizona.edu-oai-arizona.openrepository.com-10150-610333 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-arizona.edu-oai-arizona.openrepository.com-10150-6103332016-05-22T03:02:05Z Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene de Winter, J. M. Joureau, B. Sequeira, V. Clarke, N. F. van der Velden, J. Stienen, G. J. Granzier, H. Beggs, A. H. Ottenheijm, C. A. Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center Amsterdam INMR, The Children's Hospital at Westmead and Discipline of Paediatrics & Child Health, University of Sydney Department of Physics and Astronomy, Faculty of Science, VU University Department of Cellular and Molecular Medicine, University of Arizona Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School Calcium-sensitizer Levosimendan Muscle force Muscle mechanics Nebulin Nemaline myopathy BACKGROUND: Nemaline myopathy (NM), the most common non-dystrophic congenital myopathy, is characterized by generalized skeletal muscle weakness, often from birth. To date, no therapy exists that enhances the contractile strength of muscles of NM patients. Mutations in NEB, encoding the giant protein nebulin, are the most common cause of NM. The pathophysiology of muscle weakness in NM patients with NEB mutations (NEB-NM) includes a lower calcium-sensitivity of force generation. We propose that the lower calcium-sensitivity of force generation in NEB-NM offers a therapeutic target. Levosimendan is a calcium sensitizer that is approved for use in humans and has been developed to target cardiac muscle fibers. It exerts its effect through binding to slow skeletal/cardiac troponin C. As slow skeletal/cardiac troponin C is also the dominant troponin C isoform in slow-twitch skeletal muscle fibers, we hypothesized that levosimendan improves slow-twitch muscle fiber strength at submaximal levels of activation in patients with NEB-NM. METHODS: To test whether levosimendan affects force production, permeabilized slow-twitch muscle fibers isolated from biopsies of NEB-NM patients and controls were exposed to levosimendan and the force response was measured. RESULTS: No effect of levosimendan on muscle fiber force in NEB-NM and control skeletal muscle fibers was found, both at a submaximal calcium level using incremental levosimendan concentrations, and at incremental calcium concentrations in the presence of levosimendan. In contrast, levosimendan did significantly increase the calcium-sensitivity of force in human single cardiomyocytes. Protein analysis confirmed that the slow skeletal/cardiac troponin C isoform was present in the skeletal muscle fibers tested. CONCLUSIONS: These findings indicate that levosimendan does not improve the contractility in human skeletal muscle fibers, and do not provide rationale for using levosimendan as a therapeutic to restore muscle weakness in NEB-NM patients. We stress the importance of searching for compounds that improve the calcium-sensitivity of force generation of slow-twitch muscle fibers. Such compounds provide an appealing approach to restore muscle force in patients with NEB-NM, and also in patients with other neuromuscular disorders. 2015 Article de Winter et al. Skeletal Muscle (2015) 5:12 DOI 10.1186/s13395-015-0037-7 25949787 10.1186/s13395-015-0037-7 [doi] http://hdl.handle.net/10150/610333 http://arizona.openrepository.com/arizona/handle/10150/610333 2044-5040 Skeletal Muscle PMC4422316 en http://skeletalmusclejournal.biomedcentral.com/articles/10.1186/s13395-015-0037-7 © 2015 de Winter et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) BioMed Central |
collection |
NDLTD |
language |
en |
sources |
NDLTD |
topic |
Calcium-sensitizer Levosimendan Muscle force Muscle mechanics Nebulin Nemaline myopathy |
spellingShingle |
Calcium-sensitizer Levosimendan Muscle force Muscle mechanics Nebulin Nemaline myopathy de Winter, J. M. Joureau, B. Sequeira, V. Clarke, N. F. van der Velden, J. Stienen, G. J. Granzier, H. Beggs, A. H. Ottenheijm, C. A. Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene |
description |
BACKGROUND: Nemaline myopathy (NM), the most common non-dystrophic congenital myopathy, is characterized by generalized skeletal muscle weakness, often from birth. To date, no therapy exists that enhances the contractile strength of muscles of NM patients. Mutations in NEB, encoding the giant protein nebulin, are the most common cause of NM. The pathophysiology of muscle weakness in NM patients with NEB mutations (NEB-NM) includes a lower calcium-sensitivity of force generation. We propose that the lower calcium-sensitivity of force generation in NEB-NM offers a therapeutic target. Levosimendan is a calcium sensitizer that is approved for use in humans and has been developed to target cardiac muscle fibers. It exerts its effect through binding to slow skeletal/cardiac troponin C. As slow skeletal/cardiac troponin C is also the dominant troponin C isoform in slow-twitch skeletal muscle fibers, we hypothesized that levosimendan improves slow-twitch muscle fiber strength at submaximal levels of activation in patients with NEB-NM. METHODS: To test whether levosimendan affects force production, permeabilized slow-twitch muscle fibers isolated from biopsies of NEB-NM patients and controls were exposed to levosimendan and the force response was measured. RESULTS: No effect of levosimendan on muscle fiber force in NEB-NM and control skeletal muscle fibers was found, both at a submaximal calcium level using incremental levosimendan concentrations, and at incremental calcium concentrations in the presence of levosimendan. In contrast, levosimendan did significantly increase the calcium-sensitivity of force in human single cardiomyocytes. Protein analysis confirmed that the slow skeletal/cardiac troponin C isoform was present in the skeletal muscle fibers tested. CONCLUSIONS: These findings indicate that levosimendan does not improve the contractility in human skeletal muscle fibers, and do not provide rationale for using levosimendan as a therapeutic to restore muscle weakness in NEB-NM patients. We stress the importance of searching for compounds that improve the calcium-sensitivity of force generation of slow-twitch muscle fibers. Such compounds provide an appealing approach to restore muscle force in patients with NEB-NM, and also in patients with other neuromuscular disorders. |
author2 |
Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center Amsterdam |
author_facet |
Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center Amsterdam de Winter, J. M. Joureau, B. Sequeira, V. Clarke, N. F. van der Velden, J. Stienen, G. J. Granzier, H. Beggs, A. H. Ottenheijm, C. A. |
author |
de Winter, J. M. Joureau, B. Sequeira, V. Clarke, N. F. van der Velden, J. Stienen, G. J. Granzier, H. Beggs, A. H. Ottenheijm, C. A. |
author_sort |
de Winter, J. M. |
title |
Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene |
title_short |
Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene |
title_full |
Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene |
title_fullStr |
Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene |
title_full_unstemmed |
Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene |
title_sort |
effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene |
publisher |
BioMed Central |
publishDate |
2015 |
url |
http://hdl.handle.net/10150/610333 http://arizona.openrepository.com/arizona/handle/10150/610333 |
work_keys_str_mv |
AT dewinterjm effectoflevosimendanonthecontractilityofmusclefibersfromnemalinemyopathypatientswithmutationsinthenebulingene AT joureaub effectoflevosimendanonthecontractilityofmusclefibersfromnemalinemyopathypatientswithmutationsinthenebulingene AT sequeirav effectoflevosimendanonthecontractilityofmusclefibersfromnemalinemyopathypatientswithmutationsinthenebulingene AT clarkenf effectoflevosimendanonthecontractilityofmusclefibersfromnemalinemyopathypatientswithmutationsinthenebulingene AT vanderveldenj effectoflevosimendanonthecontractilityofmusclefibersfromnemalinemyopathypatientswithmutationsinthenebulingene AT stienengj effectoflevosimendanonthecontractilityofmusclefibersfromnemalinemyopathypatientswithmutationsinthenebulingene AT granzierh effectoflevosimendanonthecontractilityofmusclefibersfromnemalinemyopathypatientswithmutationsinthenebulingene AT beggsah effectoflevosimendanonthecontractilityofmusclefibersfromnemalinemyopathypatientswithmutationsinthenebulingene AT ottenheijmca effectoflevosimendanonthecontractilityofmusclefibersfromnemalinemyopathypatientswithmutationsinthenebulingene |
_version_ |
1718274643514621952 |